Financings
ZYUS Life Sciences Corporation Announces Closing of Fourth Tranche of Secured Loan Financing
Clinical-stage biotech secures incremental insider debt to fund working capital amid Phase 2a trial completion and filing delays.
Executive Summary
- ZYUS Life Sciences Corporation closed the fourth tranche of its secured loan financing on June 24, 2026.
- Gross proceeds from this tranche total CAD$50,000, bringing the cumulative secured loan balance to CAD$695,000.
- The lender is a board member, classifying the transaction as a related-party transaction under Multilateral Instrument 61-101.
- The loan carries a 12% annual interest rate, matures in six months, and is secured by a general security agreement pending TSX Venture Exchange approval.
- Net proceeds are allocated to general working capital.
- The total facility size remains capped at CAD$2,000,000, with the company indicating expectations to close additional tranches.
- Regulatory exemptions were utilized for valuation and minority shareholder approval requirements.
Material Impact
- The financing provides incremental working capital but is immaterial in absolute terms relative to clinical-stage development costs.
- The reliance on a related-party lender and the small tranche size signal continued dependence on internal capital rather than institutional or public market funding.
- The 12% interest rate and six-month maturity create near-term refinancing pressure, though prepayment is allowed without penalty.
- The news does not alter the company's fundamental trajectory, clinical timeline, or compliance status. It is a routine extension of a previously announced facility.
- Given the stock's prolonged consolidation at $0.50 and the expected nature of the funding, the market impact is limited to minor liquidity reassurance.
ZYUS · Price
Company Overview
- ZYUS Life Sciences is a clinical-stage biotechnology company focused on developing non-opioid pain therapeutics.
- The lead candidate, Trichomylin® softgel capsules, is a cannabichromene (CBC) formulation currently in Phase 2a testing for cancer-related pain.
- The company recently secured a second U.S. patent for a CBC formulation targeting neuropathic pain, expanding its intellectual property portfolio.
- In June 2026, management announced a strategic realignment to wind down international operations and focus exclusively on drug development, accompanied by the departure of the Chief Strategy and Investment Officer.
- The company trades on the TSX Venture Exchange under the ticker ZYUS.
More from ZYUS Life Sciences Corporation
Jun 17, 2026 · 21:12